

Research Article

Synthesis of *N*-(2,3-dihydro-1-[¹⁴C]methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-benzamide and *N*-(2,3-dihydro-1-[¹⁴C]methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-*N*-[¹⁴C]methylbenzamide as novel carbon-14 labelled CCK antagonists

Hojatollah Matloubi^{1,*}, Ali Khalaj², Reza Dowlatabadi^{2,†} and Gholamhossein Shirvani¹

¹ Nuclear Research Center/AEOI, Chemical Division PO Box 11365-8486, Tehran, Iran

² Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Science, Tehran, Iran

Summary

Two benzodiazepine CCK antagonists *N*-(2,3-dihydro-1-[¹⁴C]methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-benzamide **2** and *N*-(2,3-dihydro-1-[¹⁴C]methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-[¹⁴C]methylbenzamide **3** were synthesized in high yields through the reaction of *N*-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-benzamide **1** with [¹⁴C] methyl iodide in different situations. Copyright © 2002 John Wiley & Sons, Ltd.

Key Words: cholecystokinin antagonists; benzodiazepine; carbon-14; methylations

*Correspondence to: H. Matloubi, Nuclear Research Center/AEOI, Chemical Division, PO Box 11365-8486, Tehran, Iran. E-mail: hmatloubi@seai.neda.net.ir

†A part of Ph.D thesis.

Introduction and discussion

Dealkylation and 3-hydroxylation are the most important metabolic routes for several 1,4-benzodiazepine derivatives.¹ Isotopic substitution at the site of metabolic transformation is one of the best methods for elucidating the mechanism of the metabolic process and several carbon-14 labelled benzodiazepine derivatives have been synthesized and their metabolic fates studied in human and animal models.¹⁻⁶ Since the isolation of the non-peptidal cholecystokinin (CCK) antagonist Asperlicin,⁷ the 1,4-benzodiazepine ring system has served as a useful tool for delineating the pharmacologic action of CCK.


In order to study the rate of 1-dealkylation of benzodiazepine CCK antagonists and its influence on the pharmacologic profile of these compounds it became necessary to synthesize a CCK antagonist derivate labelled with carbon-14 at the N-1 position. Furthermore in order to determine the rate of chain *N*-methyl dealkylation, synthesis of a ligand, *N*-methylated both in N-1 and the amide chain appeared of interest.

The ¹⁴C labelling step in synthesis of **2** and **3** consists of methylation of **1** with [¹⁴C] methyl iodide, prepared by the known methods^{8,9} from barium [¹⁴C] carbonate via [¹⁴C] methanol. The benzodiazepine CCK antagonist **1** was prepared through a benzotriazole-assisted synthetic route from benzamide and 2-aminobenzophenone.¹⁰

By utilization of molar equivalents of **1** and [¹⁴C] methyl iodide and a short reaction time, the mono methylated product **2** in which only the N-1 of the benzodiazepine ring is methylated, is obtained. Using [¹⁴C] methyl iodide in excess and extending the reaction time yields the dimethyl derivative **3**.

Both compounds **2** and **3** were synthesized for the first time and their structures were determined by IR, MS, ¹H NMR and ¹³C NMR spectroscopy.

Biological studies on these compounds are currently under investigation.



Reaction Time: 5min. **2** R₁=¹⁴CH₃, R₂=H
 45min. **3** R₁=R₂=¹⁴CH₃

Experimental

Radioactivity determinations were carried out with a liquid scintillation counter (Beckman LS 6500) using an internal standard method. Thin layer chromatography (TLC) analyses were carried out on silica gel coated foils (Schleicher & Schull) and the spots visualized under UV (254 nm). Melting points were determined on a Reichert hot plate apparatus and are uncorrected. ^1H NMR and ^{13}C NMR were recorded on a Varian Unity Plus 400 spectrometer (399.866 MHz for ^1H NMR and 100.556 MHz for ^{13}C NMR). Mass spectra were obtained on a Finnigan TSQ-70 instrument. Infrared spectra were recorded on a Nicolet Magna IR 550 spectrometer.

$[^{14}\text{C}]$ *Methanol*. According to a modification of the method of Cox *et al.*⁸ $[^{14}\text{C}]$ carbon dioxide generated from $[^{14}\text{C}]$ barium carbonate (15.4 mCi, 0.197 g, 1 mmol) was introduced into a suspension of lithium aluminium hydride (0.16 g, 4.2 mmol) in tetrahydrofurfuryloxy-tetrahydropyran (7 ml) and the mixture stirred for 1 h at room temperature. Addition of tetrahydrofurfuryl alcohol (3.5 ml) and heating the system at 110°C with passing a slow stream of nitrogen into the reaction mixture gave $[^{14}\text{C}]$ methanol (14 mCi, 29.2 mg, 0.91 mmol). The latter was stored in dry ice.

$[^{14}\text{C}]$ *Methyl iodide*. A solution of $[^{14}\text{C}]$ methanol (14 mCi, 29.2 mg, 0.91 mmol) in 55% hydrogen iodide (4 ml) was heated at 40–90°C for 30 min. Distillation of the reaction mixture by passing a slow nitrogen stream and redistillation of the distillate on a vacuum line gave $[^{14}\text{C}]$ methyl iodide (13.8 mCi, 28.8 mg, 0.9 mmol).

N-(2,3-Dihydro-1- $[^{14}\text{C}]$ methyl-2-oxo-5-phenyl-1-HI,4-Benzodiazepin-3-yl)-benzamide **2**. Fresh sodium hydride (60% dispersion in mineral oil, 40 mg, 1 mmol) was added to a solution of **1** (355 mg, 1 mmol) in anhydrous DMF (4 ml) at 0°C under a nitrogen atmosphere. After 5 min $[^{14}\text{C}]$ methyl iodide (15.3 mCi, 31.9 mg, 1 mmol) was added via a micropipette and the reaction mixture stirred for 5 min. The reaction mixture was then added to a vigorously stirred solution of water (25 ml) containing aqueous sodium hydrogen sulfate (0.5 ml, 1 N).

The reaction slurry was filtered after 5 min and washed with water, ether and cold methanol and dried under high vacuum. Recrystallization from ethylacetate/*n*-hexan (6:4) gave pure **2** (12 mCi, 295 mg, 0.8 mmol), m.p. 242°C, ^1H NMR (δ , CDCl_3): 3.51 (s, 3H, methyl), 5.71 (d, 1H, $J=8$ Hz, CH), 7.38–7.63 (m, 12H, aromatics), 7.95 (d, 2H, $J=8$ Hz, aromatics), 8.03 (d, 1H, $J=8$ Hz, amide NH) ppm; ^{13}C NMR

(δ , CDCl_3): 35.37, 67.58, 121.51, 124.55, 127.36, 128.22, 128.52, 129.13, 129.83, 130.67, 130.77, 131.76, 131.87, 134.00, 138.09, 142.80, 166.93, 167.41, 167.83; IR (KBr): ν = 691.9, 778.9, 1516.4, 1644.4, 1690.5, 3052.6, 3277.9; mass: m/z = 369.

N-(2,3-dihydro-1-[^{14}C]methyl-2-oxo-5-phenyl-1-*H*,4-Benzodiazepin-3-yl)-*N*-[^{14}C]methyl-benzamide **3**. Fresh sodium hydride (60% dispersion in mineral oil, 80 mg, 2 mmol) was added to a solution of **1** (355 mg, 1 mmol) in anhydrous DMF (4 ml) at 0°C under a nitrogen atmosphere. After 45 min [^{14}C] methyl iodide (30.6 mCi, 63.8 mg, 2 mmol) was added via a micropipette and the reaction mixture stirred for 45 min. The reaction mixture was then added to a vigorously stirred solution of water (25 ml) containing aqueous sodium hydrogen sulfate (0.5 ml, 1 N).

The reaction slurry was filtered after 5 min and washed with water, ether and cold methanol and dried under high vacuum. Recrystallization from ethylacetate/*n*-hexan (1:9) gave pure **3** (21.4 mCi, 268 mg, 0.7 mmol), m.p. 179°C, ^1H NMR (δ , CDCl_3): 3.45 (s, 3H, methyl), 3.47(s, 3H, methyl), 6.18 (s, 1H, CH), 7.42-7.60 (m, 12H, aromatics), 7.70 (d, 2H, J = 8 Hz, aromatics) ppm; ^{13}C NMR (δ , CDCl_3): 35.03, 35.35, 72.14, 121.73, 124.05, 127.21, 127.30, 128.24, 128.96, 129.59, 129.75, 130.22, 130.64, 131.83, 136.58, 138.26, 143.26, 166.61, 168.69, 172.56; IR (KBr): ν = 687.4, 1081.1, 1357.4, 1450.3, 1624.8, 1685.5, 2921.2, 3267.9; mass: m/z = 383.

References

1. Maksay G, Tegye Z, Otvos L. *J Chem Soc Perkin Trans* 1988; **11**: 57.
2. Hsu RSP, Stolle WT. *J Labelled Cpd Radiopharm* 1981; **18**: 881.
3. Tegye Z, Maksay G, Otvos L. *J Labelled Cpd Radiopharm* 1979; **16**: 377.
4. Nakatsuka I, Kawahara K, Kamada T, Shono F, Yoshitake A. *J Labelled Cpd Radiopharm* 1977; **13**: 453.
5. Gottschalk LA, Merlis S. *Pharmacokinetics of Psychoactive Drugs*, Spectrum Publication, Inc.: New York, 1976; 45-60.
6. Kaegi HH, Burger W, Bader GJ. *J Labelled Cpd Radiopharm* 1982; **19**: 289.
7. Chang RSL, Lotti VJ, Monaghan RL, Birnbaum J, Stepley EO, Goetz MA, Albers-Schonberg G, Patcett AA, Liesch JM, Hensens OO, Springer JP. *Science* 1985; **230**: 177.
8. Cox JD, Turner HS. *J Chem Soc* 1950; 3167.
9. Ronzio AR, Murray A. *J Am Chem Soc* 1952; **74**: 2408.
10. Khalaj A, Pirali M, Matloubi H, Dowlatabadi R. *Monatsh Chem* 2001; **132**: 747.